Chugai Pharmaceutical Statistics
Total Valuation
Chugai Pharmaceutical has a market cap or net worth of 72.36 billion. The enterprise value is 66.99 billion.
Market Cap | 72.36B |
Enterprise Value | 66.99B |
Important Dates
The next estimated earnings date is Thursday, January 30, 2025.
Earnings Date | Jan 30, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.01% |
Shares Change (QoQ) | +0.01% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 639.51M |
Valuation Ratios
The trailing PE ratio is 26.79.
PE Ratio | 26.79 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 5.82 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.43, with an EV/FCF ratio of 27.34.
EV / Earnings | 24.80 |
EV / Sales | 9.23 |
EV / EBITDA | 18.43 |
EV / EBIT | 19.52 |
EV / FCF | 27.34 |
Financial Position
The company has a current ratio of 5.89
Current Ratio | 5.89 |
Quick Ratio | 4.67 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 67,522.21 |
Financial Efficiency
Return on equity (ROE) is 23.20% and return on invested capital (ROIC) is 20.24%.
Return on Equity (ROE) | 23.20% |
Return on Assets (ROA) | 17.37% |
Return on Capital (ROIC) | 20.24% |
Revenue Per Employee | 1.05M |
Profits Per Employee | 355,215 |
Employee Count | 7,604 |
Asset Turnover | 0.59 |
Inventory Turnover | 1.22 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.10% in the last 52 weeks. The beta is 0.53, so Chugai Pharmaceutical's price volatility has been lower than the market average.
Beta (5Y) | 0.53 |
52-Week Price Change | +17.10% |
50-Day Moving Average | 22.61 |
200-Day Moving Average | 20.29 |
Relative Strength Index (RSI) | 49.28 |
Average Volume (20 Days) | 109,555 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chugai Pharmaceutical had revenue of 7.97 billion and earned 2.70 billion in profits. Earnings per share was 1.64.
Revenue | 7.97B |
Gross Profit | 5.62B |
Operating Income | 3.77B |
Pretax Income | 3.77B |
Net Income | 2.70B |
EBITDA | 3.96B |
EBIT | 3.77B |
Earnings Per Share (EPS) | 1.64 |
Balance Sheet
Cash & Cash Equivalents | 5.90B |
Total Debt | n/a |
Net Cash | 5.90B |
Net Cash Per Share | n/a |
Equity (Book Value) | 12.57B |
Book Value Per Share | 7.64 |
Working Capital | 8.58B |
Cash Flow
In the last 12 months, operating cash flow was 2.93 billion and capital expenditures -477.49 million, giving a free cash flow of 2.45 billion.
Operating Cash Flow | 2.93B |
Capital Expenditures | -477.49M |
Free Cash Flow | 2.45B |
FCF Per Share | n/a |
Margins
Gross margin is 70.48%, with operating and profit margins of 47.29% and 33.87%.
Gross Margin | 70.48% |
Operating Margin | 47.29% |
Pretax Margin | 47.29% |
Profit Margin | 33.87% |
EBITDA Margin | 49.64% |
EBIT Margin | 47.29% |
FCF Margin | 30.73% |
Dividends & Yields
Chugai Pharmaceutical does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 34.45% |
Buyback Yield | -0.01% |
Shareholder Yield | -0.01% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
The last stock split was on July 6, 2020. It was a forward split with a ratio of 12.
Last Split Date | Jul 6, 2020 |
Split Type | Forward |
Split Ratio | 12 |
Scores
Chugai Pharmaceutical has an Altman Z-Score of 23.76.
Altman Z-Score | 23.76 |
Piotroski F-Score | n/a |